Table 1 Demographic and clinical characteristics of treatment or control group before and after propensity score adjustment
Treatment group (n = 232) | Unadjusted | Adjusted including baseline SUA | Adjusted including preoperative SUA | ||||
|---|---|---|---|---|---|---|---|
Control group (n = 604) | Absolute standardized difference | Control group | Absolute standardized difference | Control group | Absolute standardized difference | ||
Age (years), mean ± SD | 65.8 ± 14.0 | 61.4 ± 15.2 | 0.33 | 64.8 ± 13.7 | 0.069 | 66.4 ± 13.5 | 0.042 |
Male sex, % | 91.8 | 87.9 | 0.13 | 89.4 | 0.082 | 90.1 | 0.059 |
eGFR (ml/min/1.73 m2), mean ± SD | 82.5 ± 50.2 | 81.0 ± 36.3 | 0.03 | 80.8 ± 41.9 | 0.037 | 80.6 ± 28.4 | 0.036 |
Baseline (Pre-treatment) SUA (mg/dL), mean ± SD | 9.19 ± 1.57 | 7.76 ± 0.88 | 1.12 | 8.92 ± 1.11 | 0.198 | ||
Preoperative SUA (mg/dL), mean ± SD | 5.47 ± 2.28 | 1.33 | 5.78 ± 1.61 | 0.157 | |||
Urinary lithiasis, % | 3.4 | 1.5 | 0.13 | 2.8 | 0.04 | 3.6 | 0.01 |
Hypertension, % | 65.5 | 39.4 | 0.54 | 58.0 | 0.16 | 61.7 | 0.08 |
Ischemic heart disease, % | 34.5 | 18.9 | 0.36 | 32.1 | 0.05 | 35.8 | 0.03 |
Heart failure, % | 35.8 | 19.4 | 0.37 | 30.1 | 0.12 | 31.9 | 0.08 |
Diabetes mellitus, % | 37.9 | 25.0 | 0.28 | 35.5 | 0.05 | 36.2 | 0.04 |
Cancer, % | 63.4 | 51.8 | 0.23 | 62.3 | 0.02 | 55.3 | 0.17 |
Liver disease, % | 37.1 | 18.2 | 0.43 | 32.6 | 0.10 | 33.3 | 0.08 |
Diuretics, % | 19.8 | 15.7 | 0.11 | 17.1 | 0.07 | 17.7 | 0.05 |
ACE inhibitors, % | 9.9 | 4.4 | 0.21 | 9.2 | 0.02 | 8.1 | 0.06 |
ARBs, % | 18.5 | 9.8 | 0.25 | 17.7 | 0.02 | 17.9 | 0.02 |
Antibiotics, % | 37.1 | 31.5 | 0.12 | 34.3 | 0.06 | 33.8 | 0.07 |
NSAIDs, % | 57.3 | 49.5 | 0.16 | 55.1 | 0.04 | 50.6 | 0.14 |
Anticancer drugs, % | 1.7 | 3.0 | 0.08 | 1.5 | 0.07 | 1.2 | 0.04 |
Contrast media, % | 9.1 | 8.8 | 0.01 | 8.9 | 0.01 | 9.0 | 0.003 |
Surgeries, %, mean [range] | 0.8 [0.4–4.3] | 0.8 [0.2–7.0] | 0.06 [0–0.301] | 0.8 [0.1–4.6] | 0.04 [0–0.188] | 0.8 [0.1–4.5] | 0.04 [0–0.175] |